Research Topics
| N KatsumataSummaryAffiliation: National Cancer Center Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemNoriyuki Katsumata
Department of Medical Oncology, National Cancer Center, Tokyo, Japan
Jpn J Clin Oncol 38:777-85. 2008..This study was conducted to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in Japanese patients with Müllerian carcinoma having a therapeutic history of platinum-based chemotherapy...
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialNoriyuki Katsumata
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Lancet 374:1331-8. 2009..Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer...- Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)N Katsumata
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Ann Oncol 20:1210-5. 2009..This randomized, multicenter, phase III trial compared doxorubicin plus cyclophosphamide (AC), single-agent docetaxel (D), and an alternating regimen of AC and docetaxel (AC-D) as first-line chemotherapy in metastatic breast cancer (MBC)... - Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancerN Katsumata
Department of Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Ann Oncol 22:1353-7. 2011..S-1 is an oral fluoropyrimidine. This phase II study was designed to evaluate the efficacy and safety of S-1 in patients with advanced or recurrent uterine cervical cancer... - Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative StudyN Katsumata
Department of Medical Oncology, National Cancer Center Hospital, 104 0045 Tokyo, Japan
Br J Cancer 93:999-1004. 2005.... - Docetaxel: an alternative taxane in ovarian cancerN Katsumata
Department of Medical Oncology, National Cancer Centre Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
Br J Cancer 89:S9-S15. 2003.... - Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapyK Hashimoto
Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Ann Oncol 21:2195-200. 2010..The aim of this study was to develop a prediction model of progressive disease (PD) in breast cancer patients without measurable disease in first-line chemotherapy... - Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapyM Tanioka
Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Br J Cancer 103:297-302. 2010..This study was designed to identify factors predictive of recurrence in patients with pCR... - FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancerK Tamura
Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Ann Oncol 22:1302-7. 2011..This prospective phase II trial aimed to evaluate whether these polymorphisms are associated with clinical efficacies in patients who received trastuzumab... 
Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapyS Akashi-Tanaka
Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan
Int J Cancer 96:66-73. 2001..In conclusion, CE-CT is the most accurate noninvasive technique for identifying the extent of the residual carcinoma after neoadjuvant chemotherapy if cases of IBC and ILC are excluded...- Efficacy of pleurodesis for malignant pleural effusions in breast cancer patientsT Hirata
Dept of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo 104 0045, Japan
Eur Respir J 38:1425-30. 2011..24. Our results suggest that the efficacy of P-ST may be superior to that of ST alone with respect to local control of pleural effusions in breast cancer patients... - Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)H Nomura
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
Ann Oncol 22:636-42. 2011..The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma... - A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative studyN Katsumata
National Cancer Center Hospital, Tokyo, Japan
Ann Oncol 11:1531-6. 2000..This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer... - Irinotecan plus carboplatin for patients with carcinoma of unknown primary siteK Yonemori
Breast and Medical Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
Br J Cancer 100:50-5. 2009..Therefore, the regimen may be one of the potentially available chemotherapeutic options for community standard of care in patients with a good performance status... - Clinical characteristics and outcomes of women with stage IV endometrial cancerM Tanioka
Division of Breast and Medical Oncology, National Cancer Center Hospital Tokyo, Tsukiji 5 1 1, Chuo Ku, Tokyo, Japan
Med Oncol 27:1371-7. 2010..In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment. The indication for surgery should be carefully considered in this subset of patients... - Compliance with Good Clinical Practice in oncology registration trials in JapanK Yonemori
Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 103 0045, Japan
Ann Oncol 22:1451-6. 2011.... - A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancerM Ando
Department of Medicine, National Cancer Center Hospital, Tokyo, Japan
Br J Cancer 77:1937-43. 1998..The recommended doses of docetaxel and 5-day continuous infusion of 5-FU for a phase II trial are 50 mg m(-2) and 500 mg m(-2) per day every 3 or 4 weeks... - Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistanceM Ando
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
J Clin Oncol 19:336-42. 2001..The status of anthracycline resistance is important for the prediction of response to second-line treatment with docetaxel... - Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicinT Takahashi
Breasr Surgery Division, National Cancer Hospital, Tokyo, Japan
Breast Cancer 8:234-7. 2001..There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer... - Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favorN Katsumata
Department of Medical Oncology, Nippon Medical School, Musashikosugi Hospital, 1 396 Kosugi machi, Nakahara ku, Kawasaki City, Kanagawa Prefecture, Japan
Ann Oncol 22:viii29-viii32. 2011..0015], as was the overall survival at 3 years (72.1% versus 65.1%; HR 0.75; 95% CI: 0.57-0.98; P=0.03). Dose-dense weekly paclitaxel plus carboplatin represents a new treatment option in women with advanced epithelial ovarian cancer... - Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancerN Katsumata
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Cancer Chemother Pharmacol 43:441-4. 1999..In order to clinically confirm these promising preclinical observations, we performed a phase II trial of KRN8602 in patients with anthracycline-resistant metastatic breast cancer... - Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterusT Kasamatsu
Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
Br J Cancer 88:245-50. 2003.... - Mental adjustment to first recurrence and correlated factors in patients with breast cancerY Okano
Psycho Oncology Division, National Cancer Center Research Institute East, Chiba, Japan
Breast Cancer Res Treat 67:255-62. 2001.... - Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerT Hirata
Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 104 0045, Japan
Br J Cancer 101:1529-36. 2009..To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC)... - Three novel PHEX gene mutations in Japanese patients with X-linked hypophosphatemic ricketsK Sato
Department of Pediatrics, Hokkaido University School of Medicine, N15, W7, Kita ku, Sapporo, Japan 060 8638
Pediatr Res 48:536-40. 2000..These results suggest that: 1) PHEX gene mutations are responsible for XLH in Japanese patients, and 2) PHEX gene mutations are heterogeneous in the Japanese population similarly to other ethnic populations... - Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208Yutaka Tokuda
Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259 1193, Japan
Cancer Sci 99:145-51. 2008..78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival...